contract_awardAwarded Monday, July 20, 2026Analyzed

MAYO CLINIC: $32.4M Department of Health and Human Services Federal Award

Neutral

Summary

The NIH awarded Mayo Clinic a $32.4M contract for continued biobank operations for the All of Us precision medicine program. As a private entity, no publicly traded companies directly benefit, but the contract underscores continued federal investment in precision medicine infrastructure.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Mayo Clinic continues as lead biobank for All of Us program.
  • 2.Precision medicine remains a federal priority.
  • 3.No direct public company beneficiary from this contract.

Market Implications

This contract does not move any publicly traded stocks. The All of Us program's continued funding indicates steady demand for biobanking services, which could benefit private companies like LabCorp or Quest in related areas, but this contract is exclusive to Mayo Clinic.

Full Analysis

The Department of Health and Human Services, through the National Institutes of Health, awarded a $32.4M direct financial aid contract to Mayo Clinic to sustain and expand the All of Us Research Program's biobank. The contract covers 2025-2027 and aims to maintain biospecimen collection, storage, distribution, and support pediatric and ancillary studies. Mayo Clinic is a private non-profit academic medical center, not a publicly traded company. No public company is the direct recipient, parent, or recognized subsidiary. While precision medicine initiatives broadly benefit healthcare research, this specific contract does not flow directly to any public company.

No related bills from the provided list show a direct connection to this biobank contract. Most bills are neutral with low impact and cover disparate sectors like manufacturing, infrastructure, or defense. The contract is a continuation of a program established in 2017, and similar awards for biobanking have historically been renewed without immediate public market implications.

Because the recipient is private, no supply chain or competitor analysis is warranted per guidelines—guessing would produce false positives. Investors should note the ongoing federal commitment to precision medicine but recognize that this contract's value is not linked to any publicly traded equity.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Exec OrderJun 25, 2026

Advancing Regenerative Agriculture and Strengthening American Farm Resilience

This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.

Exec OrderJun 3, 2026

Implementing Schedule Policy/Career in the Excepted Service

This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.

Contract Details

Recipient

MAYO CLINIC

Award Amount

$32,432,744

Awarding Agency

Department of Health and Human Services

Sub-Agency

National Institutes of Health

Contract Type

DIRECT PAYMENT FOR SPECIFIED USE, AS A SUBSIDY OR OTHER NON-REIMBURSABLE DIRECT FINANCIAL AID (C)

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →